Introduction: In the REFLECT trial, lenvatinib was found to be noninferior compared to
sorafenib in terms of overall survival. Here, we analyze the effects of lenvatinib in the real-life …

Abstract Background Advanced Hepatocarcinoma (HCC) is an important health problem
worldwide. Recently, the REFLECT trial demonstrated the non‐inferiority of Lenvatinib …

Abstract Background and Aims Recently, lenvatinib demonstrated non‐inferiority to
sorafenib in terms of overall survival (OS) in a randomized phase III study that was …

Background Lenvatinib has been approved in Italy since October 2019 as a first-line therapy
for advanced hepatocellular carcinoma (HCC) and to date data on effectiveness and safety …

Purpose Sorafenib is the only approved drug in first-line treatment for hepatocellular
carcinoma. Recently, the Phase III REFLECT trial proved lenvatinib not inferior to sorafenib …

Background Lenvatinib is approved as first-line treatment for patients with advanced
hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world patients …

There is limited evidence on the efficacy of lenvatinib in advanced hepatocellular carcinoma
(HCC) patients. Aim of this meta-analysis was to compare lenvatinib and sorafenib as first …

Sorafenib has been the standard therapy for patients with unresectable hepatocellular
carcinoma (HCC) since 2007, when it was shown to prolong survival, as verified in the …

Background: The present study aimed to assess the efficacy and safety of lenvatinib and
verify the possibility of lenvatinib for the expanded indication from the REFLECT trial in …

Background In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1–3, FGF receptors
1–4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed …